InBioGen Co Ltd (101140) - Total Liabilities
Based on the latest financial reports, InBioGen Co Ltd (101140) has total liabilities worth ₩2.44 Billion KRW (≈ $1.65 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore 101140 shareholders equity momentum to track the company's year-over-year net asset growth rate.
InBioGen Co Ltd - Total Liabilities Trend (2013–2024)
This chart illustrates how InBioGen Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See InBioGen Co Ltd free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
InBioGen Co Ltd Competitors by Total Liabilities
The table below lists competitors of InBioGen Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Culp, Inc. Common Stock
NYSE:CULP
|
USA | $70.53 Million |
|
Goldbank Mining Corp
V:GLB
|
Canada | CA$18.02 Million |
|
Opnet Technologies Co Ltd
TWO:8034
|
Taiwan | NT$137.78 Million |
|
Tracxn Technologies Limited
NSE:TRACXN
|
India | Rs456.47 Million |
|
OpenSys M Bhd
KLSE:0040
|
Malaysia | RM42.72 Million |
|
Star Equity Holdings Inc
NASDAQ:STRR
|
USA | $47.52 Million |
|
Haverty Furniture Companies Inc
NYSE:HVT-A
|
USA | $345.68 Million |
|
Concraft Holding Co Ltd
TW:4943
|
Taiwan | NT$2.75 Billion |
Liability Composition Analysis (2013–2024)
This chart breaks down InBioGen Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is InBioGen Co Ltd worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.01 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.01 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how InBioGen Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for InBioGen Co Ltd (2013–2024)
The table below shows the annual total liabilities of InBioGen Co Ltd from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩2.89 Billion ≈ $1.96 Million |
+10.42% |
| 2023-12-31 | ₩2.62 Billion ≈ $1.78 Million |
-92.99% |
| 2022-12-31 | ₩37.40 Billion ≈ $25.35 Million |
-61.22% |
| 2021-12-31 | ₩96.45 Billion ≈ $65.36 Million |
+408.31% |
| 2020-12-31 | ₩18.97 Billion ≈ $12.86 Million |
-23.87% |
| 2019-12-31 | ₩24.92 Billion ≈ $16.89 Million |
+2472.55% |
| 2018-12-31 | ₩968.80 Million ≈ $656.54K |
-53.09% |
| 2017-12-31 | ₩2.07 Billion ≈ $1.40 Million |
-68.82% |
| 2016-12-31 | ₩6.62 Billion ≈ $4.49 Million |
-2.00% |
| 2015-12-31 | ₩6.76 Billion ≈ $4.58 Million |
+126.40% |
| 2014-12-31 | ₩2.99 Billion ≈ $2.02 Million |
-52.87% |
| 2013-12-31 | ₩6.33 Billion ≈ $4.29 Million |
-- |
About InBioGen Co Ltd
INBIOGEN Co., Ltd. engages in the manufacture and distribution of footwear products in South Korea. It is also involved in distribution of wood pellets; kiosk; and food and beverage businesses. The company was formerly known as BTONE CO.,Ltd. INBIOGEN Co., Ltd. was founded in 1949 and is headquartered in Seoul, South Korea.